Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.7400
0.00 (0.00%)
Jun 30, 2025, 4:00 PM EDT
5.71%
Market Cap 34.27M
Revenue (ttm) n/a
Net Income (ttm) -3.85M
Shares Out 46.31M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,500
Average Volume 27,798
Open 0.7400
Previous Close 0.7400
Day's Range 0.7200 - 0.7400
52-Week Range 0.5100 - 0.8800
Beta 0.80
RSI 49.74
Earnings Date Aug 22, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.